The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Ripp T.M.

Department of Arterial Hypertension, Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia

Rebrova T.Yu.

Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia

Mordovin V.F.

Department of Arterial Hypertension, Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia

Afanasyev S.A.

Research Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia

Pekarsky S.E.

Research Institute of Cardiology, Tomsk, Russia

Semke G.V.

Research Institute of Cardiology, Tomsk, Russia

Falkovskaya A.Yu.

Research Institute of Cardiology, Tomsk, Russia

Lichikaki V.A.

Research Institute of Cardiology, Tomsk, Russia

Tsymbalyuk E.V.

Research Institute of Cardiology, Tomsk, Russia

Criteria for selecting patients with resistant hypertension for a renal sympathetic denervation

Authors:

Ripp T.M., Rebrova T.Yu., Mordovin V.F., Afanasyev S.A., Pekarsky S.E., Semke G.V., Falkovskaya A.Yu., Lichikaki V.A., Tsymbalyuk E.V.

More about the authors

Journal: Therapeutic Archive. 2016;88(8): 14‑18

Read: 2553 times


To cite this article:

Ripp TM, Rebrova TYu, Mordovin VF, et al. Criteria for selecting patients with resistant hypertension for a renal sympathetic denervation. Therapeutic Archive. 2016;88(8):14‑18. (In Russ.)
https://doi.org/10.17116/terarkh201688814-18

References:

  1. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31(7):1295-1297. doi:10.1016/j.rec.2013.07.015
  2. Mancia G, Laurent S, Agabiti-Rosei E at al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158. doi:10.3109/ 08037050903 450468
  3. Urban D, Ewen S, Ukena C, et al. Treating resistant hypertension: role of renal denervation. Integr Blood Press Control. 2013;11(6):119-128.  doi:10.2147/ibpc.s33958
  4. Calhoun DA, Jones D, Textor S et al; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):510-526.  doi:10.1161/hypertensionaha.108.189141
  5. Daugherty SL, Powers JD, Magid DJ et al. Resistant hypertension. Incidence and prognosis of resistant hypertension in hypertensive patients. J Circulation. 2012;125(13):1635-1642. doi:10.1161/circulationaha.111.068064
  6. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. J Hypertens. 2009;54(4):690-697.  doi:10.1161/hypertensionaha.108.119883
  7. Mancia G, Grassi G, Giannattasio C et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. J Hypertens. 1999;34:724-728.  doi:10.1161/01.hyp.34.4.724
  8. Stryuk S, Dlusskaya I. Adrenoreaktivnost i serdechno-sosudistaya sistema. Moscow; 2003. (In Russ.)
  9. Bunova S, Ostapenko V, Nikolaev N, Nelidova A, Kuzukova A, Troshkina T, Moskvina U. Arterial hypertension and adrenoreactivity: characteristics in patients with obesity. Byulleten SO RAMN. 2008;1(129):77-81. (In Russ.)
  10. Krum H, Barman N, Schlaich M et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. J Hypertensn. 2011;57 (5):911-917.  doi:10.1161/hypertensionaha.110.163014
  11. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomized controlled trial. J Lancet. 2010;376:1903-1609. doi:10.1016/s0140-6736(10)62039-9
  12. Mahfoud F, Linz D, Mancia G et al. Renal artery denervation for treatment of hypertensive patients with or without obstructive sleep apnea and resistant hypertension: results from the global symplicity registry. J Hypertens. 2015;33(Suppl 1):e108.
  13. Briasoulis A, Bakris G. Renal Denervation After SYMPLICITY HTN-3: Where Do We Go? Can J Cardiol. 2015;31(5):642-648.  doi:10.1016/j.cjca.2014.12.004
  14. Sapoval M, Azizi M. Renal artery denervation for the treatment of resistant hypertension. Update after Medtronic announcement that its Symplicity HTN3 study failed to meet its primary efficacy end point. Diagn Interv Imag. 2014;95(4):353-354.  doi:10.1016/j.diii.2014.02.022
  15. Bauer A et al. A scoring system for identification of responders to renal sympathetic denervation. Eur Heart J. 2014;35:1190.
  16. Ripp T, Mordovin V, Pekarskiy S et al. Cardioprotective effects of renal denervation in resistant hypertension: efficiency predictors. Arterial’naya Gipertenziya. Arterial Hypertension. 2014;20(6):28-133. (In Russ.) doi:10.1097/01.hjh.0000468497.97663.2a

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.